Reported Utilities and Health-Related Quality of Life (HRQOL) Data for Patients with Muscle Invasive Urothelial Carcinoma (MIUC) Treated with Radical Resection (RR): A Systematic Literature Review (SLR)
Author(s)
Trip AM1, Chami N2, Teitsson S3, Broughton E4, May JR3, Kurt M5, Alleman C6
1OPEN Health - Evidence & Access, Rotterdam, ZH, Netherlands, 2OPEN Health - Evidence & Access, Oxford, UK, 3Bristol Myers Squibb, Uxbridge, UK, 4Bristol Myers Squibb, Princeton, NJ, USA, 5Bristol Myers Squibb, Lawrenceville, NJ, USA, 6OPEN Health - Evidence & Access, Rotterdam, Netherlands
OBJECTIVES : To systematically collect utility values or HRQoL data that can be translated into utility values via mapping methods for MIUC patients treated with RR. METHODS : An SLR was conducted by two independent reviewers to identify publications up to February 13, 2021. Inclusion criteria were studies reporting utility values or HRQoL data for MIUC patients treated with RR measured with bladder cancer specific or inclusive, cancer specific or general instruments. Databases and sources included: MEDLINE (In-Process), Embase, EconLit, CRD NHS EED, CRD HTA, conference proceedings and HTA websites. RESULTS : In total, 23 publications reporting HRQoL data from 23 distinct studies were identified. These studies mostly had one of three designs: prospective (n=12), retrospective (n=6), or cross-sectional (n=4). For one study, the design was unclear. Studies were conducted globally; most frequently in the US (n=4), followed by Germany (n=3), Italy (n=3), Japan (n=3), and the UK (n=3). Most studies (n=18) compared HRQoL for different RR approaches in patients with muscle-invasive bladder cancer. One study compared utility values for multiple MIUC health states (neoadjuvant chemotherapy followed by RR, transurethral resection with concurrent chemoradiation (CRT), CRT with salvage cystectomy, and recurrent as well as metastatic bladder cancer). No study reported HRQoL data related to adjuvant treatment after RR. Two studies reported utility values related to RR, either elicited with standard gamble method and visual analogue scale (n=1), or measured using EQ-5D-3L (n=1). In other studies, the EORTC QLQ-C30 was the most frequently used instrument (n=11), followed by FACT-G (n=6), EORTC QLQ-BLM30 (n=5), SF-36 (n=5), SF-12 (n=1) and HADS (n=1). In general, results of these studies show impaired HRQoL for MIUC patients treated with RR compared to general population. CONCLUSIONS : RR-specific HRQoL data are available; however, further research is needed to assess the impact of adjuvant treatment after RR on HRQoL for MIUC patients.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSA342
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Drugs, Oncology, Surgery